Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08IRG
|
|||
| Former ID |
DNCL002478
|
|||
| Drug Name |
BIIB 015
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Teratocarcinoma-derived growth factor 1 (TDGF1) | Target Info | . | [1] |
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Regulation of signaling by NODAL | |||
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | ||||
| WikiPathways | Signaling by NODAL | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.